Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis

Jun Shi, Yan Zhao, Takefumi Ishii, Wenyang Hu, Selcuk Sozer, Wei Zhang, Edward Bruno, Valerie Lindgren, Mingjiang Xu, Ronald Hoffman

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Idiopathic myelofibrosis (IM) is likely the consequence of both the acquisition of genetic mutations and epigenetic changes that silence critical genes that control cell proliferation, differentiation, and apoptosis. We have explored the effects of the sequential treatment with the DNA methyltransferase inhibitor, decitabine [5-aza-2′-deoxycytidine (5azaD)], followed by the histone deacetylase inhibitor, trichostatin A (TSA), on the behavior of IM CD34+ cells. Unlike normal CD34+ cells where 5azaD/TSA treatment leads to the expansion of CD34+ cells and marrow-repopulating cells, treatment of IM CD34+ cells results in a reduction of the number of total cells, CD34+ cells, and assayable hematopoietic progenitor cells (HPC). In IM, HPCs are either heterozygous or homozygous for the JAK2V617F mutation or possess wild-type JAK2 in varying proportions. Exposure of IM CD34+ cells to 5azaD/TSA resulted in a reduction of the proportion of JAK2V617Fpositive HPCs in 83% of the patients studied and the reduction in the proportion of homozygous HPCs in 50% of the patients. 5azaD/TSA treatment led to a dramatic reduction in the number of HPCs that contained chromosomal abnormalities in two JAK2V617F-negative IM patients. IM is characterized by constitutive mobilization of HPCs, which has been partly attributed to decreased expression of the chemokine receptor CXCR4. Treatment of IM CD34+ cells with 5azaD/TSA resulted in the up-regulation of CXCR4 expression by CD34+ cells and restoration of their migration in response to SDF-1. These data provide a rationale for sequential therapy with chromatin-modifying agents for patients with IM.

Original languageEnglish (US)
Pages (from-to)6417-6424
Number of pages8
JournalCancer Research
Volume67
Issue number13
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

decitabine
Primary Myelofibrosis
trichostatin A
Chromatin
Therapeutics
Mutation
Histone Deacetylase Inhibitors
Chemokine Receptors
Methyltransferases
Proxy
Hematopoietic Stem Cells
Epigenomics
Chromosome Aberrations
Cell Differentiation
Up-Regulation
Cell Count
Bone Marrow
Cell Proliferation
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shi, J., Zhao, Y., Ishii, T., Hu, W., Sozer, S., Zhang, W., ... Hoffman, R. (2007). Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Research, 67(13), 6417-6424. https://doi.org/10.1158/0008-5472.CAN-07-0572

Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. / Shi, Jun; Zhao, Yan; Ishii, Takefumi; Hu, Wenyang; Sozer, Selcuk; Zhang, Wei; Bruno, Edward; Lindgren, Valerie; Xu, Mingjiang; Hoffman, Ronald.

In: Cancer Research, Vol. 67, No. 13, 01.07.2007, p. 6417-6424.

Research output: Contribution to journalArticle

Shi, J, Zhao, Y, Ishii, T, Hu, W, Sozer, S, Zhang, W, Bruno, E, Lindgren, V, Xu, M & Hoffman, R 2007, 'Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis', Cancer Research, vol. 67, no. 13, pp. 6417-6424. https://doi.org/10.1158/0008-5472.CAN-07-0572
Shi, Jun ; Zhao, Yan ; Ishii, Takefumi ; Hu, Wenyang ; Sozer, Selcuk ; Zhang, Wei ; Bruno, Edward ; Lindgren, Valerie ; Xu, Mingjiang ; Hoffman, Ronald. / Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. In: Cancer Research. 2007 ; Vol. 67, No. 13. pp. 6417-6424.
@article{169a6b85670e4217a9d67ae5c456c434,
title = "Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis",
abstract = "Idiopathic myelofibrosis (IM) is likely the consequence of both the acquisition of genetic mutations and epigenetic changes that silence critical genes that control cell proliferation, differentiation, and apoptosis. We have explored the effects of the sequential treatment with the DNA methyltransferase inhibitor, decitabine [5-aza-2′-deoxycytidine (5azaD)], followed by the histone deacetylase inhibitor, trichostatin A (TSA), on the behavior of IM CD34+ cells. Unlike normal CD34+ cells where 5azaD/TSA treatment leads to the expansion of CD34+ cells and marrow-repopulating cells, treatment of IM CD34+ cells results in a reduction of the number of total cells, CD34+ cells, and assayable hematopoietic progenitor cells (HPC). In IM, HPCs are either heterozygous or homozygous for the JAK2V617F mutation or possess wild-type JAK2 in varying proportions. Exposure of IM CD34+ cells to 5azaD/TSA resulted in a reduction of the proportion of JAK2V617Fpositive HPCs in 83{\%} of the patients studied and the reduction in the proportion of homozygous HPCs in 50{\%} of the patients. 5azaD/TSA treatment led to a dramatic reduction in the number of HPCs that contained chromosomal abnormalities in two JAK2V617F-negative IM patients. IM is characterized by constitutive mobilization of HPCs, which has been partly attributed to decreased expression of the chemokine receptor CXCR4. Treatment of IM CD34+ cells with 5azaD/TSA resulted in the up-regulation of CXCR4 expression by CD34+ cells and restoration of their migration in response to SDF-1. These data provide a rationale for sequential therapy with chromatin-modifying agents for patients with IM.",
author = "Jun Shi and Yan Zhao and Takefumi Ishii and Wenyang Hu and Selcuk Sozer and Wei Zhang and Edward Bruno and Valerie Lindgren and Mingjiang Xu and Ronald Hoffman",
year = "2007",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-07-0572",
language = "English (US)",
volume = "67",
pages = "6417--6424",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis

AU - Shi, Jun

AU - Zhao, Yan

AU - Ishii, Takefumi

AU - Hu, Wenyang

AU - Sozer, Selcuk

AU - Zhang, Wei

AU - Bruno, Edward

AU - Lindgren, Valerie

AU - Xu, Mingjiang

AU - Hoffman, Ronald

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Idiopathic myelofibrosis (IM) is likely the consequence of both the acquisition of genetic mutations and epigenetic changes that silence critical genes that control cell proliferation, differentiation, and apoptosis. We have explored the effects of the sequential treatment with the DNA methyltransferase inhibitor, decitabine [5-aza-2′-deoxycytidine (5azaD)], followed by the histone deacetylase inhibitor, trichostatin A (TSA), on the behavior of IM CD34+ cells. Unlike normal CD34+ cells where 5azaD/TSA treatment leads to the expansion of CD34+ cells and marrow-repopulating cells, treatment of IM CD34+ cells results in a reduction of the number of total cells, CD34+ cells, and assayable hematopoietic progenitor cells (HPC). In IM, HPCs are either heterozygous or homozygous for the JAK2V617F mutation or possess wild-type JAK2 in varying proportions. Exposure of IM CD34+ cells to 5azaD/TSA resulted in a reduction of the proportion of JAK2V617Fpositive HPCs in 83% of the patients studied and the reduction in the proportion of homozygous HPCs in 50% of the patients. 5azaD/TSA treatment led to a dramatic reduction in the number of HPCs that contained chromosomal abnormalities in two JAK2V617F-negative IM patients. IM is characterized by constitutive mobilization of HPCs, which has been partly attributed to decreased expression of the chemokine receptor CXCR4. Treatment of IM CD34+ cells with 5azaD/TSA resulted in the up-regulation of CXCR4 expression by CD34+ cells and restoration of their migration in response to SDF-1. These data provide a rationale for sequential therapy with chromatin-modifying agents for patients with IM.

AB - Idiopathic myelofibrosis (IM) is likely the consequence of both the acquisition of genetic mutations and epigenetic changes that silence critical genes that control cell proliferation, differentiation, and apoptosis. We have explored the effects of the sequential treatment with the DNA methyltransferase inhibitor, decitabine [5-aza-2′-deoxycytidine (5azaD)], followed by the histone deacetylase inhibitor, trichostatin A (TSA), on the behavior of IM CD34+ cells. Unlike normal CD34+ cells where 5azaD/TSA treatment leads to the expansion of CD34+ cells and marrow-repopulating cells, treatment of IM CD34+ cells results in a reduction of the number of total cells, CD34+ cells, and assayable hematopoietic progenitor cells (HPC). In IM, HPCs are either heterozygous or homozygous for the JAK2V617F mutation or possess wild-type JAK2 in varying proportions. Exposure of IM CD34+ cells to 5azaD/TSA resulted in a reduction of the proportion of JAK2V617Fpositive HPCs in 83% of the patients studied and the reduction in the proportion of homozygous HPCs in 50% of the patients. 5azaD/TSA treatment led to a dramatic reduction in the number of HPCs that contained chromosomal abnormalities in two JAK2V617F-negative IM patients. IM is characterized by constitutive mobilization of HPCs, which has been partly attributed to decreased expression of the chemokine receptor CXCR4. Treatment of IM CD34+ cells with 5azaD/TSA resulted in the up-regulation of CXCR4 expression by CD34+ cells and restoration of their migration in response to SDF-1. These data provide a rationale for sequential therapy with chromatin-modifying agents for patients with IM.

UR - http://www.scopus.com/inward/record.url?scp=34447118173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447118173&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0572

DO - 10.1158/0008-5472.CAN-07-0572

M3 - Article

C2 - 17616702

AN - SCOPUS:34447118173

VL - 67

SP - 6417

EP - 6424

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -